COMPASS PATHWAYS PLC (CMPS) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-161.14M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.43× | Operating cash flow / net income. Period ending 2026-06-30. $-161.14M ÷ $-376.09M ≈ 0.43× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -161.14M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -376.09M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-161.14M | (m) | (m) | (m) | (m) | $-376.09M | (m) | (m) | (m) | 0.43× |
| 2026-03-31 | (m) | (m) | $-159.52M | (m) | (m) | (m) | (m) | $-160.70M | (m) | (m) | (m) | 0.99× |
| 2025-12-31 | (m) | (m) | $-157.24M | (m) | (m) | (m) | (m) | $-287.86M | (m) | (m) | (m) | 0.55× |
| 2025-09-30 | (m) | (m) | $-161.21M | (m) | (m) | (m) | (m) | $-237.32M | (m) | (m) | (m) | 0.68× |
| 2025-06-30 | (m) | (m) | $-148.29M | (m) | (m) | (m) | (m) | $-138.10M | (m) | (m) | (m) | 1.07× |
| 2025-03-31 | (m) | (m) | $-144.01M | (m) | (m) | (m) | (m) | $-137.80M | (m) | (m) | (m) | 1.05× |
| 2024-12-31 | $-119.19M | (m) | $-119.19M | $0.00 | (m) | (m) | (m) | $-155.12M | (m) | (m) | (m) | 0.77× |
| 2024-09-30 | $-105.21M | (m) | $-105.21M | $0.00 | (m) | (m) | (m) | $-144.32M | (m) | (m) | (m) | 0.73× |
| 2024-06-30 | $-100.10M | (m) | $-100.08M | $18.00K | (m) | (m) | (m) | $-139.21M | (m) | (m) | (m) | 0.72× |
| 2024-03-31 | $-90.52M | (m) | $-90.48M | $37.00K | (m) | (m) | (m) | $-129.44M | (m) | (m) | (m) | 0.70× |
| 2023-12-31 | $-97.44M | (m) | $-97.38M | $66.00K | (m) | (m) | (m) | $-118.46M | (m) | (m) | (m) | 0.82× |
| 2023-09-30 | $-115.07M | (m) | $-114.90M | $173.00K | (m) | (m) | (m) | $-116.86M | (m) | (m) | (m) | 0.98× |
| 2023-06-30 | $-117.01M | (m) | $-116.86M | $150.00K | (m) | (m) | (m) | $-101.84M | (m) | (m) | (m) | 1.15× |
| 2023-03-31 | $-110.59M | (m) | $-110.05M | $543.00K | (m) | (m) | (m) | $-94.54M | (m) | (m) | (m) | 1.16× |
| 2022-12-31 | $-106.05M | (m) | $-105.45M | $596.00K | (m) | (m) | (m) | $-91.50M | (m) | (m) | (m) | 1.15× |
| 2022-09-30 | $-83.10M | (m) | $-82.52M | $582.00K | (m) | (m) | (m) | $-86.23M | (m) | (m) | (m) | 0.96× |
| 2022-06-30 | $-78.06M | (m) | $-77.39M | $673.00K | (m) | (m) | (m) | $-83.71M | (m) | (m) | (m) | 0.92× |
| 2022-03-31 | $-77.44M | (m) | $-77.09M | $346.00K | (m) | (m) | (m) | $-80.20M | (m) | (m) | (m) | 0.96× |
| 2021-12-31 | $-68.08M | (m) | $-67.75M | $334.00K | (m) | (m) | (m) | $-71.74M | (m) | (m) | (m) | 0.94× |
| 2021-09-30 | $-62.40M | (m) | $-62.13M | $268.00K | (m) | (m) | (m) | $-64.90M | (m) | (m) | (m) | 0.96× |
| 2021-06-30 | $-62.34M | (m) | $-62.15M | $193.00K | (m) | (m) | (m) | $-65.74M | (m) | (m) | (m) | 0.95× |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-64.46M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-41.51M | (m) | $-41.38M | $131.00K | (m) | (m) | (m) | $-60.33M | (m) | (m) | (m) | 0.69× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-17.98M | (m) | $-17.81M | $165.00K | (m) | (m) | (m) | $-19.61M | (m) | (m) | (m) | 0.91× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |